Decreasing the production or removing circulating DAMPs in uremia and anti-inflammatory treatments that target the NLRP3 to IL-1 to IL-6 pathway of innate immunity may offer a new paradigm to treat CKD-related PEW and CVD. Here, IL1B is linked to chronic kidney disease.